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Abstract
Background: Indications for implantable cardioverter defibrillator (ICD) implantation have
expanded considerably in recent years, resulting in steadily growing numbers of ICD recipients
worldwide. The aim of this study was to review the overall experience with ICDs in Iceland.
Methods: This was a retrospective single centre study set at the University Hospital in Iceland.
Data on all ICD implantations in Iceland from the first implantation in 1992 till the end of 2002 was
reviewed.
Results: Sixty-two patients (71% male) received an ICD during this period. There was an increase
in the number of implants by year and the number of new implants in 2001 and 2002 amounted to
56 and 38 per million, respectively. The mean age at implantation was 58 (+/-14) years. Forty
patients (65%) had coronary artery disease. The most common indications for ICD implantation
were cardiac arrest, 32 (52%) and another 26 (42%) had experienced ventricular tachycardia
without cardiac arrest. The most common adverse event was inappropriate shocks. Twenty-eight
patients (45%) received therapy from their ICDs, with the majority receiving appropriate therapy.
Of the thirteen patients deceased before or during the study period, no case of sudden arrhythmic
death was observed.
Conclusion: This study shows that the experience with ICDs in Iceland is in most respects similar
to other Western countries.
Background
The use of implantable cardioverter defibrillators (ICDs)
for management of ventricular arrhythmias has become
an increasingly popular option since Mirowsky and col-
leagues first introduced the device in 1980 [1]. Following
the publication of several large multi-center trials in the
last few years, indications for implantation have
expanded considerably and now include prophylactic
implantation for patients with coronary artery disease and
a severely depressed ejection fraction [2-4]. This has
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growing numbers of ICD recipients worldwide, especially
in the United States and Western Europe [5].
The objective of this study was to review the experience
with ICDs in Iceland where the first ICD implant was per-
formed in 1992. On account of Iceland's small popula-
tion of approximately 300.000, all of these patients attend
the same outpatient clinic at the University Hospital in
Reykjavik. Therefore, we were able to review information
on every implantation that had been done in the country
from the beginning, and as such, examine the experience
with ICD therapy in a whole population setting.
Methods
Design and subjects
This was a retrospective study, set at the University Hospi-
tal in Reykjavik, reviewing all ICD implantations in Ice-
land from the first implantation in 1992 to the end of year
2002. The study was reviewed and approved by the Insti-
tutional Review Committee of Landspitali University
Hospital and the Icelandic Data Protection Authority, and
complied with the declaration of Helsinki. Informed con-
sent was received from all patients who were alive at the
time of the study.
Data collection and analysis
The following data was collected: Age at implantation;
gender; presence or absence of structural heart disease;
indication for implantation; ejection fraction (EF) prior to
implantation; length of the surgical procedure; type of
procedure; surgical complications; adverse events; length
of follow up; therapy delivered by the device; malfunc-
tions; reasons for reoperations and causes of death for
deceased patients. Information was retrieved from the
University Hospital medical records and the ICD outpa-
tient clinic records. Information on EF was retrieved from
the latest echocardiogram or ventriculogram performed
within one year prior to implantation. When EF was
recorded by echocardiography only an estimate was given
instead of a single number. For this reason we categorized
the EF into four categories: less than 20%, 21–40%, 41–
60% and more than 60%. Causes of death were retrieved
from the National Death Registry.
When evaluating the cause of delivered therapy by the
ICD, stored documentation of shocks and antitachycardia
pacing-therapy (ATP) was reviewed. Stored electrograms
where available in the the devices implanted in Iceland
after1994. As such the majority of ICDs in the patients
studied had stored electrograms available. Therapy was
categorized as appropriate, inappropriate or indetermi-
nate. Therapy on account of malfunction of the device or
documented tachyarrhythmia of atrial origin was defined
as inappropriate. Therapy was defined as indeterminate if
it could not be categorized as either appropriate or inap-
propriate. All patients on whom events were evaluated
had either stored electrograms or printouts of or event
recordings showing a plot of RR intervals during an event.
If neither was present the episode was classified as indeter-
minate with regards to outcome. A single investigator
evaluated the stored electrograms and RR plots, with con-
sultation from a second investigator when deemed necc-
essary.
Therapy was considered effective if the ventricular rate
after shock/ATP delivery was <65% of the ventricular rate
before shock/ATP delivery. Therapy was classified as caus-
ing acceleration of the arrhythmia if ventricular rate was ≥
than 20% faster after shock/ATP delivery than prior to
therapy. All ATP given for the same episode of a ventricu-
lar tachyarrhythmia was considered a single therapy.
Assessment of effectiveness in such episodes was confined
to outcome of the last ATP-therapy given. All data are pre-
sented as means ± SD.
Results
The patients
The demographic and clinical data is shown in Table 1.
Sixty-two patients received an ICD in Iceland from the
first implantation in April 1992 to the end of December
2002. Prior to the first operation in Iceland one Icelandic
patient had received an ICD in Sweden in 1990. He later
had generator changes twice in Iceland. Out of these sixty-
two patients 44 were male (71%). The mean age at
implantation was 58 (+/-14) years (range 16–80 years).
Indications for ICD implantations, classified in accord-
ance to AHA/ACC Implantation of Pacemaker and
Antiarrhythmia Guidelines, were cardiac arrest due to ven-
tricular fibrillation (VF) or ventricular tachycardia (VT) in
thirty-two patients (52%), VT without cardiac arrest in
twenty-six patients (42%) and syncope with inducible VT/
VF at an electrophysiological study (EPS) in four patients
(6%) [2]. No primary prophylactic implantation was per-
formed.
The majority of the patients 40 (65%) had coronary artery
disease (CAD). Seven patients (11%) had long QT-syn-
drome (LQTS) and six (10%) had dilated cardiomyopa-
thy. The following cardiac disease was present in one
patient each: hypertrophic cardiomyopathy, coronary
artery spasm (refractory to vasodilator therapy and with
polymorphic VT) and cardiac amyloidosis. Seven patients
(11%) suffered from VT or VF without any demonstrable
cardiac illness. Thirty-six patients (60%) had an EF over
40%, including 24 who had an EF >60%. Two deceased
patients had no retrievable records of EF.Page 2 of 8
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The number of primary implantations and re-operations
each year is shown in Figure 1. A total of sixty-one primary
implantations and nineteen re-operations were done in
the period reviewed. One patient received an ICD in the
first year, (1992). Almost two-thirds of the implantations
(64%) were performed in the last three years (2000–
2002). As can be seen from figure 1 the number of new
implants increased each year, although tapering slightly
off in the last year. In 2001 and 2002 the number of new
implants amounted to 56 and 38 per million, respec-
tively.
The length of the operations decreased during the study
period. In the years 1992–1997 the mean operating time
were 2:21 hours, compared to 1:20 hours in the years
1998–2002.
All operations were done with a non-thoracotomy
approach. Of the sixty-one primary implantations and ten
re-operations where a new device was implanted, sixty-
four (90%) were implanted subpectorally and seven
(10%) under the rectus abdominis muscle. The tran-
venous lead insertion was usually via the subclavian vein
(89%) but on rare occasions the lead was inserted through
the cephalic vein (11%).
Nineteen re-operations were performed involving four-
teen patients (Table 2). Twelve out of the nineteen reoper-
ations were related to lead malfunctions; decreased
sensing in leads without apparent macroscopic damage at
inspection (8), lead insulation damage (2) and minor dis-
lodgement of leads (2). Four elective generator changes
were done due to battery depletion. Two reoperations
were performed primarily because of inappropriate
shocks and one because of loss of connection to the device
after shock delivery. No apparent malfunction was dem-
onstrated during detailed lead inspection in any of these
three cases.
Surgical complications and long-term adverse events
These are shown in Table 3. The most common surgical
complication was minor bleeding into the device pocket
(7). Other surgical complications included serous fluid
causing localized swelling in the device pocket (2), pleural
effusion (3), and hemothorax (1). In the early postopera-
Table 3: Short term (less than 30 days post operatively) and long 
term (more than 30 days post operatively) adverse events (AE).
Short term AE (less than 30 days post operatively): no. of patients
Haematoma/haemorrhage 7
Seroma 2
Pleural effusion 3
Hemothorax 1
Superficial infection 1
Dislodgement of lead 2
Death 1
Long term AE (more than 30 days post operatively):
Inappropriate shocks
due to atrial fibrillation/flutter 5
due to lead malfunction 2
without apparent cause 3
Decreased sensing/increased pacing threshold 8
Dislodgement of device 1
Discomfort around implant site 1
Loss of connection to device after shock 1
Table 1: Patient demographic and clinical data
Age at implantation (years) Mean 58 +/- 14
Range 16–80
Gender Men 71% 44
Women 29% 18
Underlying cardiac disease Coronary artery 
disease (CAD)
62% 40
Dilated 
cardiomyopathy
11% 7
VT/VF without any 
known cardiac illness
11% 7
Long QT-syndrome 10% 6
Hypertrophic 
cardiomyopathy
2% 1
Suspected drug 
related ventricular 
arrhythmia
2% 1
Coronary artery 
spasm resulting in VT
2% 1
Cardiac amyloidosis 2% 1
Indication for implantation Cardiac arrest due to 
VT or VF*
52% 32
VT without loss of 
consciousness
42% 26
Syncope, VT/VF 
induced at EPS*
6% 4
EF prior to implantation* <20% 3% 2
21–40% 37% 22
41–60% 20% 12
>60% 40% 24
* VT = ventricular tachycardia, VF = ventricular fibrillation, EPS = 
electrophysiologial study, EF = ejection fraction.
Table 2: Indications for reoperations.
Related to leads:
Decreased sensing in leads 8
Lead or lead insulation breakdown 2
Dislodgement of lead 2
Other:
Battery depletion 4
Inappropriate shocks without apparent damage in leads/device 2
Loss of connection to device after shock 1Page 3 of 8
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was treated with antibiotics and did not result in device
removal. Two patients had micro-dislodgement of the
leads, and one patient died a week after the ICD implant.
The patient suffered from severe congestive heart failure
and deteriorated after the operation. His death was not
considered to be directly related to the operation, but
rather to the severity of his underlying illness.
The most common long-term adverse events were inap-
propriate shocks. In the cases of inappropriate shocks
without apparent cause or because of lead malfunction, a
new device and/or leads were implanted. Other long-term
adverse events were decreased sensing or increased pacing
threshold (8), dislodgement of the device (migrated to the
axilla) (1), transient discomfort around implant site (1)
and in one case there was loss of communication with the
device via the programmer wand. All of these cases except
the case of discomfort around the implant site resulted in
re-operations.
Therapy
There were 17 dual chamber devices were (24%) and 54
single chamber devices (76%) implanted. All the patients
were followed every 3 months at the same device clinic.
The mean follow up time was 29.1 +/-18.5 months (range
0.2–154.9 months).
A summary of shock- and ATP therapy is shown in figures
2 and 3. Twenty-eight patients (45%) received therapy
from their ICD during the period studied. Three of the
twenty-eight patients were deceased at the time of the data
collection and detailed information on therapy for these
three patients were unavailable. Thus, a total of 222
shocks and 331 ATP-treatments received by 25 patients
were reviewed. The mean number of shocks per patient
was 9.7 (range 1–43). The mean number of ATP-therapies
per patient was 6.5 (range 1–96).
The majority (84%) of the 25 patients had appropriate
therapy at some time from their device. When reviewing
effectiveness, 69% of the shocks and 48% of the ATP treat-
ments were effective in reducing the ventricular rate by ≥
35% which we defined as successful. None of the appro-
priate shocks caused acceleration of the arrhythmia, but
5% of the appropriate ATP treatments caused acceleration,
eventually leading to a shock.
Out of the twenty-five patients receiving treatment, ten
(40%) at some point received inappropriate shocks and/
or ATP-treatment. The median number of inappropriate
shocks was 4 (range 1–33). Four out of these ten patients
received inappropriate shocks because of either device or
lead malfunction. The remaining six received inappropri-
ate shocks because of atrial arrhythmias. Three of those six
patients had dual chamber ICDs. Three patients received
the vast majority of inappropriate shocks; 33, 30 and 17
shocks each (83% of the total number of inappropriate
shocks). Two received multiple inappropriate shocks
because of atrial fibrillation, including one with a dual
chamber device. That patient underwent AV-nodal abla-
tion and has not received an inappropriate shock after
this. The third patient received 33 shocks on the same day
because of device malfunction.
In the majority of cases, inappropriate treatments due to
atrial arrhythmias did not result in cardioversion to sinus
rhythm. On one occasion, an inappropriate shock for
atrial fibrillation resulted in ventricular fibrillation. Three
inappropriate ATP-treatments lead to shocks by accelera-
tion of the ventricular rate in atrial fibrillation into the VF
zone.
Survival
Thirteen patients with an ICD died prior to the end of
2002. Eight patients (62%) had a cardiac cause of death;
three from acute myocardial infarction resulting in acute
heart failure and five from end stage heart failure. No case
of sudden arrhythmic death was observed. Two patients
died from cancer, two from subarachnoidal haemorrhage
and one from bacterial sepsis, unrelated to the device.
Discussion
In this retrospective study we reviewed sixty-one primary
ICD implantations and nineteen re-operations performed
in Iceland from the first implantation in April 1992 till the
end of December 2002. Major complications and serious
adverse events were rare, with the most common long-
term adverse event being inappropriate shocks. The
majority of patients that received therapy from the device
had such appropriately, with 69% of the shocks and 48%
of the ATP treatments effectively terminating the arrhyth-
mia.
The main strengths of this study are that it examines the
experience with ICD treatment in the Icelandic popula-
tion as a whole, including every single ICD implantation
in the country from the first implantation in 1992 till the
end of year 2002. This gives an opportunity to evaluate
the effectiveness of ICD therapy in this small community.
At the same time the study's major limitation is probably
its small sample size and retrospective design.
The age distribution of our patient population was similar
to previous studies on this subject [6-9]. The percentage of
women was somewhat higher than observed in other
studies, or 29% compared to 10–20% [6-9]. Sixty-two per-
cent of our patient population had coronary artery disease
as an underlying cardiac illness, which is somewhat lower
than observed in other studies [6,7,9-11]. This might bePage 4 of 8
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drome, which is more common in women [10] and usu-
ally diagnosed at a younger age, but in our study six
patients (10%) had this diagnosis.
The mean EF of our population seemed to be somewhat
higher than observed in previous studies [7,8,11]. Forty
percent of our patient population had normal ejection
fractions and only two patients had an EF lower than
20%.
Distribution of indications according to the AHA/ACC
guidelines was similar to previous experiences [6-8,10].
Implantation rates increased rapidly over the ten-year
period as was to be expected. When comparing implanta-
tion rates in Iceland to other European countries,
implants in Iceland account to 56 and 38 per million pop-
ulation in the last two years studied, respectively, which is
comparable to the current implant rates of around 45 per
million in Western Europe [5,13].
In our study, all of the operations were done by non-tho-
racotomy approach. No serious infections resulting in
device explantation were seen during the study period.
Infection rates in ICD patients have been reported to be
from 0–8% [14-16]. The fact that all the operations in this
study were performed in an operating theatre, as opposed
to an electrophysiology laboratory and a rigorous prophy-
lactic antibiotics scheme applied may help explain the
low infection rate seen here.
The incidence of haematomas and pleural effusions was
somewhat higher than observed in previous studies
[6,8,14]. All of the devices were implanted subpectorally
or under the rectus abdominis, and this may possibly
explain the higher incidence of haematomas and the low
infection rate.
The majority of re-operations were performed because of
leads problems, most often because of decreased sensing
of the lead. In some instances lead malfunction led to
inappropriate shocks. Our experience is consistent with
previous studies, indicating that lead-related problems
account for the large proportion of long term ICD compli-
cations [8,15-17].
Inappropriate shocks were the most common long-term
adverse event encountered in our study, but 40% (10 out
of 25) of the patients receiving shocks, received inappro-
priate therapy at some time (shocks and/or ATP-therapy).
As well as sometimes causing serious physical discomfort
for the patient, adverse psychological consequences of
multiple shocks can occur. Previous studies have reported
worse outcomes on measures of anxiety, depression and
quality of life for ICD patients receiving frequent shocks
compared to those receiving no or few shocks [19,20]. On
Yearly number of implantations and reoperationsFigure 1
Yearly number of implantations and reoperations. Number of implantations and reoperations each year from the first 
implantation in 1992 till the end of December 2002.
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tion as a whole has been shown to be comparable to or
even superior to medically treated patients with malig-
nant arrhythmias and patients with pacemakers [19,21].
In this study three out of six patients receiving inappropri-
ate therapy because of atrial arrhythmias had dual cham-
ber devices. Studies comparing single chamber devices to
dual chamber devices with regard to inappropriate ther-
apy for atrial arrhythmias have shown ambiguous results
[22,23]. Currently, a large prospective multicentre ran-
domised trial is underway, designed to analyse the ability
of dual chamber ICDs to reduce adverse events, including
inappropriate therapy, compared with single chamber
devices [24].
Advanced detection algorhythms were activated in the
devices during implant in those with known preexisting
paroxysmal atrial arrhythmias. These patients all had a
dual chamber device implanted. For those who had no
prior history of atrial arrhythmias, advanced detection
algorhythms were not activated at implant. For those who
received inappropriate shocks due to atrial arrhythmias
during follow up, advanced detection criteria were acti-
vated if the patients had a dual chamber device. Addition-
ally this led to anti-arrhythmic drug therapy if the patient
had not been taking such drugs prior to the inappropriate
shock.
The vast majority of treated patients received appropriate
therapy at some time, with 69% of the shocks and 48% of
the ATP treatments being effective in terminating the ven-
tricular arrhythmia. This success rate is somewhat less
than previous studies have shown, where as high as 83%
success for shock treatment and 78–94% for ATP treat-
ment has been reported [25-28]. However, patient selec-
tion, length of follow up, methods of classifying
appropriateness and success of therapy vary considerably
between studies, making it difficult to reliably compare
results.
No death was observed on account of sudden arrhythmic
death. While this may indicate the effectiveness of the
device to treat life threatening arrhythmias it must also be
taken into consideration that that only thirteen patients
died during or were deceased before the study period,
which may limit the extent to which conclusions can be
drawn regarding this.
Classification of shocksFigure 2
Classification of shocks. Therapy was categorized as appropriate, inappropriate or indeterminate. Therapy given to termi-
nate tachyarrhytmia of ventricular origin was defined as appropriate. Therapy on account of malfunction of the device or doc-
umented tachyarrhythmia of atrial origin was defined as inappropriate. Therapy was defined as indeterminate if it could not be 
categorized as either appropriate or inappropriate.
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In this retrospective study reviewing all ICD implanta-
tions in Iceland over a ten year period, we observed that
implantation rates have been increasing to a similar extent
as in other Western European countries. Therapy received
was most often appropriate, with an acceptable success
rate in terminating the malignant arrhythmia. Taken
together, this study indicates that experience with ICDs in
Iceland is comparative to other Western countries, with
the devices delivering effective and potentially life-saving
therapy to many of the patients. As such, the current study
supports the expanding use of ICD therapy for patients
suffering from malignant arrhythmias. At the same time
we observed that lead problems are not infrequent and
inappropriate therapy remains a problem. This under-
scores the need to focus on improving lead function qual-
ity as well as increasing the devices' arrhythmia analysing
capability, to minimize the risk of patients receiving inap-
propriate therapy.
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